Linvoseltamab dosage instructions

Linvoseltamab is a novel bispecific antibody indicated for the treatment of relapsed or refractory multiple myeloma (R/RMM). Its dosage and dosage are designed to maximize therapeutic efficacy while reducing the incidence of side effects, particularly the risk of serious reactions such as cytokine release syndrome (CRS) and neurotoxicity.

1. Medication Instructions:Linvoseltamab is administered by intravenous injection, using an ascending dose schedule to reduce the incidence and severity of adverse reactions. Before use, Linvoseltamab must be diluted with 0.9% sodium chloride injection before intravenous infusion. In addition, patients need to prepare corresponding medications before receiving treatment to ensure that they can be given in time when needed.

Linvoseltamab must be administered in a qualified medical institution by a professional healthcare provider who is capable of handling serious adverse reactions in emergency situations, including CRS, infusion-related reactions (IRR) and neurotoxicity (such as immune effector cell-associated neurotoxic syndrome, ICANS). To monitor for possible side effects, patients must be hospitalized and observed for 24 hours after the first ascending dose and the same observation after the second ascending dose.

2. Recommended dosage:The recommended dosage of Linvoseltamab is divided into multiple stages. In the initial stage, the dosage is increased, starting from 5 mg and increasing to 25 mg and 200 mg. After reaching 200 mg, patients will receive 200 mg weekly for a total of 10 treatments. Thereafter, if the patient achieves a very good partial response or better partial response at or after Week 24 and successfully receives at least 17 doses of 200 mg, a reduction in dosing frequency to 200 mg every 4 weeks may be considered.

Such an ascending dose regimen not only helps gradually adapt to the drug and improve patient tolerance, but also effectively monitors and manages possible side effects. In addition, by adjusting the dosing frequency according to the patient's condition, the therapeutic effect can be better maintained and the patient's quality of life optimized.

Reference materials:https://en.wikipedia.org/wiki/Linvoseltamab